{"success":true,"data":{"pressRelease":{"id":"153051","rtpr_id":"nBw5lV4wKa-20260925","ticker":"SRPT","exchange":"NASDAQ","all_tickers":["SRPT"],"title":"Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress","author":"Business Wire","published_at":"2026-09-25T12:30:00.227Z","article_body":"Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society\nAnnual Congress\n\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic\nmedicine for rare diseases, will present new data from its portfolio of\ntreatments for Duchenne muscular dystrophy at the 31(st) Annual Congress of\nthe World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima,\nJapan.\n\nData at WMS includes a late-breaking poster presentation on delandistrogene\nmoxeparvovec efficacy and safety in older, ambulatory Duchenne patients in\nSarepta’s clinical studies who were aged 8-12 years old at the time of\ntreatment.\n\nPoster numbers, titles and session timing are as follows:\n 1.103LBP  Functional and safety outcomes in older ambulatory patients with Duchenne        Wed., Sept. 30     \n           muscular dystrophy treated with delandistrogene moxeparvovec (C. McDonald, et    \n                  \n           al)                                                                              \n2:30-3:30 PM JST  \n                                                                                            \n                  \n                                                                                            \n1:30-2:30 AM EST  \n 2.062P    Delandistrogene moxeparvovec in Duchenne muscular dystrophy: Functional and      Wed., Sept. 30     \n           safety outcomes up to 3 years post-infusion in the EMBARK study (J. Mendell,     \n                  \n           et al)                                                                           \n5:15-6:15 PM JST  \n                                                                                            \n                  \n                                                                                            \n4:15-5:15 AM EST  \n 2.080P    Delandistrogene moxeparvovec micro-dystrophin expression and safety in           Wed., Sept. 30     \n           2–3-year-olds with Duchenne muscular dystrophy in ENDEAVOR and ENVOL studies     \n                  \n           (C. McDonald, et al)                                                             \n5:15-6:15 PM JST  \n                                                                                            \n                  \n                                                                                            \n4:15-5:15 AM EST  \n 2.044eP   Pooled safety analysis from Phase 1 to Phase 3 clinical trials of                Wed., Sept. 30     \n           delandistrogene moxeparvovec in Duchenne muscular dystrophy (C. Proud, et al)    \n                  \n                                                                                            \n5:15-6:15 PM JST  \n                                                                                            \n                  \n                                                                                            \n4:15-5:15 AM EST  \n 2.050eP   Efficacy and safety of early intervention with delandistrogene moxeparvovec in   Wed., Sept. 30     \n           DMD(MDX) mice (N. Pukos, et al)                                                  \n                  \n                                                                                            \n5:15-6:15 PM JST  \n                                                                                            \n                  \n                                                                                            \n4:15-5:15 AM EST  \n 2.067eP   Efficacy and safety of golodirsen and casimersen compared with placebo in        Wed., Sept. 30     \n           Duchenne muscular dystrophy (ESSENCE): Phase 3 results and post hoc analysis     \n                  \n           (F. Muntoni, et al)                                                              \n5:15-6:15 PM JST  \n                                                                                            \n                  \n                                                                                            \n4:15-5:15 AM EST  \n\n\nThe full WMS 2026 program is available at\nhttps://www.wms2026.com/page/programme\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.wms2026.com%2Fpage%2Fprogramme&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=https%3A%2F%2Fwww.wms2026.com%2Fpage%2Fprogramme&index=1&md5=b3fcb1043ed02a1d46c1c0e5e911603a)\n. Sarepta abstracts and presentations will be available on Sarepta.com in the\nEvents & Presentations\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestorrelations.sarepta.com%2Fevents-presentations&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=Events+%26amp%3B+Presentations&index=2&md5=70e6c6af6adc54d7df6c257e1aec0de1)\nsection following presentation at the congress.\n\nAbout ELEVIDYS (delandistrogene moxeparvovec-rokl)\n\nELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose,\nadeno-associated virus (AAV)-based gene transfer therapy for intravenous\ninfusion designed to address the underlying genetic cause of Duchenne muscular\ndystrophy – mutations or changes in the DMD gene that result in the lack of\ndystrophin protein – through the delivery of a transgene that codes for the\ntargeted production of ELEVIDYS micro-dystrophin in skeletal muscle.\n\nELEVIDYS is indicated for the treatment of ambulatory patients 4 years of age\nand older with Duchenne muscular dystrophy (DMD) who have a confirmed mutation\nin the DMD gene.\n\nLimitations of Use\n\nELEVIDYS is not recommended in patients with:\n\n\n * Preexisting liver impairment (defined as gamma-glutamyl transferase [GGT] >\n2 x upper limit of normal or total bilirubin > the upper limit of normal\nnot due to Gilbert’s syndrome) or active hepatic viral infection due to the\nhigh risk of acute serious liver injury and acute liver failure.\n\n * Recent vaccination (within 4 weeks of treatment) due to immunogenicity and\npotential safety concerns.\n\n * Active or recent (within 4 weeks) infections due to safety concerns.\n\nIMPORTANT SAFETY INFORMATION\n\nBOXED WARNING: Acute Serious Liver Injury and Acute Liver Failure\n\nAcute serious liver injury, including life-threatening and fatal acute liver\nfailure, has occurred. Patients with preexisting liver impairment may be at\nhigher risk.\n\nPrior to infusion, assess liver function by clinical examination and\nlaboratory testing. Administer systemic corticosteroids before and after\nELEVIDYS infusion. Continue to monitor liver function weekly for the first 3\nmonths after infusion and continue until results are unremarkable.\n\nInstruct patients to maintain proximity to an appropriate healthcare facility,\nas determined by the healthcare provider, for at least 2 months following\nELEVIDYS infusion.\n\nObtain prompt consultation with a specialist (e.g., gastroenterologist or\nhepatologist) if acute serious liver injury or impending acute liver failure\nis suspected.\n\nCONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in\nexon 8 and/or exon 9, including a deletion of any portion or the entirety of\nthese exons, in the DMD gene.\n\nWARNINGS AND PRECAUTIONS:\n\nAcute Serious Liver Injury and Acute Liver Failure\n\nSee Boxed Warning.\n\n\n * Acute serious liver injury marked by elevations of liver enzymes (e.g., GGT,\nALT) and total bilirubin and acute liver failure has occurred with ELEVIDYS.\nOnset of the liver injury typically begins within 8 weeks of ELEVIDYS\nadministration. In non-ambulatory patients treated with ELEVIDYS, acute liver\nfailure with fatal outcome has occurred in the clinical and post-marketing\nsettings.\n\n * Life-threatening mesenteric vein thrombosis, complicated by bowel ischemia and\nnecrosis, and portal hypertension have been reported following acute liver\ninjury associated with ELEVIDYS in a non-ambulatory patient.\n\n * Patients with preexisting liver impairment, chronic hepatic condition, or\nacute liver disease (e.g., acute hepatic viral infection) may be at higher\nrisk of acute serious liver injury or acute liver failure. Postpone ELEVIDYS\nadministration in patients with acute liver disease until resolved or\ncontrolled.\n\n * Systemic corticosteroid treatment is recommended for patients before and after\nELEVIDYS infusion. Adjust corticosteroid regimen when indicated.\n\nSerious Infections\n\n\n * Increased susceptibility to serious infections may occur due to concomitant\nadministration of corticosteroid regimen and additional immunosuppressants,\nand ELEVIDYS. Serious respiratory infections, including with fatal outcomes,\nhave occurred in patients taking immunosuppressant corticosteroids required\nfor ELEVIDYS administration.\n\n * Monitor patients for signs and symptoms of infection before and after ELEVIDYS\nadministration and treat appropriately.\n\n * Administer immunizations according to best clinical practices and immunization\nguidelines prior to initiation of the corticosteroid regimen required before\nELEVIDYS infusion.\n\n * Avoid administration of ELEVIDYS to patients with active infections.\n\nMyocarditis\n\n\n * Acute, serious, life-threatening myocarditis and troponin-I elevations have\nbeen observed within 24 hours to more than 1 year following ELEVIDYS infusion.\n\n * If a patient experiences myocarditis, those with pre-existing left ventricle\nejection fraction (LVEF) impairment may be at higher risk of adverse outcomes.\n\n * Monitor troponin-I before ELEVIDYS infusion and weekly for the first month\nfollowing infusion and continue monitoring if clinically indicated, until\nresults return to near baseline levels or stabilize.\n\n * More frequent monitoring may be warranted in the presence of cardiac symptoms,\nsuch as chest pain or shortness of breath.\n\n * Advise patients to contact a physician immediately if they experience cardiac\nsymptoms.\n\nInfusion-related Reactions\n\n\n * Infusion-related reactions, including hypersensitivity reactions and\nanaphylaxis, have occurred during or up to several hours following ELEVIDYS\nadministration. Closely monitor patients during and for at least 3 hours after\nthe end of infusion. If symptoms of infusion-related reactions occur, slow or\nstop the infusion and give appropriate treatment. Once symptoms resolve, the\ninfusion may be restarted at a lower rate.\n\n * ELEVIDYS should be administered in a setting where treatment for\ninfusion-related reactions is immediately available.\n\n * Discontinue infusion for anaphylaxis.\n\nImmune-mediated Myositis\n\n\n * Immune-mediated myositis, including serious and life-threatening events, has\noccurred approximately 1 month following ELEVIDYS infusion. Signs and symptoms\ninclude severe muscle weakness, including dysphagia, dyspnea, dysphonia, and\nhypophonia.\n\n * Severe to life-threatening immune-mediated myositis has been reported in\npatients with deletions including portions of exons 1-17 and/or exons 59-71 of\nthe DMD gene.\n\n * Regardless of genetic mutation, advise patients to contact a physician\nimmediately if they experience any unexplained increased muscle pain,\ntenderness, or weakness, including dysphagia, dyspnea, dysphonia, or\nhypophonia, as these may be symptoms of myositis. Consider additional\nimmunomodulatory treatment based on patient’s clinical presentation and\nmedical history if these symptoms occur.\n\nPreexisting Immunity against AAVrh74\n\n\n * In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede\ntransgene expression at desired therapeutic levels. Following treatment with\nELEVIDYS, all patients developed anti-AAVrh74 antibodies.\n\n * Perform baseline testing for the presence of anti-AAVrh74 total binding\nantibodies prior to ELEVIDYS administration.\n\n * ELEVIDYS administration is not recommended in patients with elevated\nanti-AAVrh74 total binding antibody titers ≥1:400.\n\nADVERSE REACTIONS\n\n\n * The most common adverse reactions (incidence ≥5%) reported in clinical\nstudies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and\ntroponin-I increased.\n\nReport negative side effects of prescription drugs to the FDA. Visit\nwww.fda.gov/medwatch\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=www.fda.gov%2Fmedwatch&index=3&md5=1a4c6e29d825d3121d98375c8ecd7bf7)\nor call 1-800-FDA-1088. You may also report side effects to Sarepta\nTherapeutics at 1-888-SAREPTA (1-888-727-3782).\n\nPlease see the full Prescribing Information\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Felevidys.com%2FPI&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=Prescribing+Information&index=4&md5=a2312ade004cd5946c44f083063b6f9c)\nfor ELEVIDYS, including Boxed Warning and Medication Guide\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.elevidys.com%2Fmed-guide&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=Medication+Guide&index=5&md5=143306c16000933c4a1065b0ef7083d2)\n.\n\nAbout Sarepta Therapeutics\n\nSarepta is on an urgent mission: engineer precision genetic medicine for rare\ndiseases that devastate lives and cut futures short. We hold a leadership\nposition in Duchenne muscular dystrophy (Duchenne) and are building a robust\nportfolio of programs across muscle, central nervous system, and cardiac\ndiseases. For more information, please visit www.sarepta.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sarepta.com&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=www.sarepta.com&index=6&md5=0d1e7f4e43ee53068f457b34bba888a0)\nor follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsarepta-therapeutics&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=LinkedIn&index=7&md5=1bcdf426a751607b7b9f1f1d88d50d29)\n, X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FSarepta&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=X&index=8&md5=f70077901282b9171c609cd7672dbddd)\n, Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.instagram.com%2Fsareptatherapeutics%2F&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=Instagram&index=9&md5=cd7c7c007249b00b56cab397d5ca2272)\nand Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.facebook.com%2FSarepta-Therapeutics-208950446535427%2F&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=Facebook&index=10&md5=d58e8ab85429b0c97863726e54ed8a14)\n.\n\nInternet Posting of Information\n\nWe routinely post information that may be important to investors in the 'For\nInvestors' section of our website at www.sarepta.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sarepta.com%2F&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=www.sarepta.com&index=11&md5=0f6992ff0ec4075243b99704bb2b3597)\n. We encourage investors and potential investors to consult our website\nregularly for important information about us.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260925573264/en/\n(https://www.businesswire.com/news/home/20260925573264/en/)\n\nInvestor Contacts:\n\nIan Estepan, 617-274-4052, iestepan@sarepta.com \n(mailto:iestepan@sarepta.com) \nRyan Wong, 617-800-4112, rwong@sarepta.com \n(mailto:rwong@sarepta.com) \nTam Thornton, 617-803-3825, tthornton@sarepta.com\n(mailto:tthornton@sarepta.com)\n\nMedia Contacts:\n\nTracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com \n(mailto:tsorrentino@sarepta.com) \nKara Hoeger, 617-710-3898, khoeger@sarepta.com (mailto:khoeger@sarepta.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw5lV4wKa-20260925","title":"Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress","author":"Business Wire","ticker":"SRPT","created":"2026-09-25T12:30:00.227Z","tickers":["SRPT"],"exchange":"NASDAQ","article_body":"Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society\nAnnual Congress\n\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic\nmedicine for rare diseases, will present new data from its portfolio of\ntreatments for Duchenne muscular dystrophy at the 31(st) Annual Congress of\nthe World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima,\nJapan.\n\nData at WMS includes a late-breaking poster presentation on delandistrogene\nmoxeparvovec efficacy and safety in older, ambulatory Duchenne patients in\nSarepta’s clinical studies who were aged 8-12 years old at the time of\ntreatment.\n\nPoster numbers, titles and session timing are as follows:\n 1.103LBP  Functional and safety outcomes in older ambulatory patients with Duchenne        Wed., Sept. 30     \n           muscular dystrophy treated with delandistrogene moxeparvovec (C. McDonald, et    \n                  \n           al)                                                                              \n2:30-3:30 PM JST  \n                                                                                            \n                  \n                                                                                            \n1:30-2:30 AM EST  \n 2.062P    Delandistrogene moxeparvovec in Duchenne muscular dystrophy: Functional and      Wed., Sept. 30     \n           safety outcomes up to 3 years post-infusion in the EMBARK study (J. Mendell,     \n                  \n           et al)                                                                           \n5:15-6:15 PM JST  \n                                                                                            \n                  \n                                                                                            \n4:15-5:15 AM EST  \n 2.080P    Delandistrogene moxeparvovec micro-dystrophin expression and safety in           Wed., Sept. 30     \n           2–3-year-olds with Duchenne muscular dystrophy in ENDEAVOR and ENVOL studies     \n                  \n           (C. McDonald, et al)                                                             \n5:15-6:15 PM JST  \n                                                                                            \n                  \n                                                                                            \n4:15-5:15 AM EST  \n 2.044eP   Pooled safety analysis from Phase 1 to Phase 3 clinical trials of                Wed., Sept. 30     \n           delandistrogene moxeparvovec in Duchenne muscular dystrophy (C. Proud, et al)    \n                  \n                                                                                            \n5:15-6:15 PM JST  \n                                                                                            \n                  \n                                                                                            \n4:15-5:15 AM EST  \n 2.050eP   Efficacy and safety of early intervention with delandistrogene moxeparvovec in   Wed., Sept. 30     \n           DMD(MDX) mice (N. Pukos, et al)                                                  \n                  \n                                                                                            \n5:15-6:15 PM JST  \n                                                                                            \n                  \n                                                                                            \n4:15-5:15 AM EST  \n 2.067eP   Efficacy and safety of golodirsen and casimersen compared with placebo in        Wed., Sept. 30     \n           Duchenne muscular dystrophy (ESSENCE): Phase 3 results and post hoc analysis     \n                  \n           (F. Muntoni, et al)                                                              \n5:15-6:15 PM JST  \n                                                                                            \n                  \n                                                                                            \n4:15-5:15 AM EST  \n\n\nThe full WMS 2026 program is available at\nhttps://www.wms2026.com/page/programme\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.wms2026.com%2Fpage%2Fprogramme&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=https%3A%2F%2Fwww.wms2026.com%2Fpage%2Fprogramme&index=1&md5=b3fcb1043ed02a1d46c1c0e5e911603a)\n. Sarepta abstracts and presentations will be available on Sarepta.com in the\nEvents & Presentations\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestorrelations.sarepta.com%2Fevents-presentations&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=Events+%26amp%3B+Presentations&index=2&md5=70e6c6af6adc54d7df6c257e1aec0de1)\nsection following presentation at the congress.\n\nAbout ELEVIDYS (delandistrogene moxeparvovec-rokl)\n\nELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose,\nadeno-associated virus (AAV)-based gene transfer therapy for intravenous\ninfusion designed to address the underlying genetic cause of Duchenne muscular\ndystrophy – mutations or changes in the DMD gene that result in the lack of\ndystrophin protein – through the delivery of a transgene that codes for the\ntargeted production of ELEVIDYS micro-dystrophin in skeletal muscle.\n\nELEVIDYS is indicated for the treatment of ambulatory patients 4 years of age\nand older with Duchenne muscular dystrophy (DMD) who have a confirmed mutation\nin the DMD gene.\n\nLimitations of Use\n\nELEVIDYS is not recommended in patients with:\n\n\n * Preexisting liver impairment (defined as gamma-glutamyl transferase [GGT] >\n2 x upper limit of normal or total bilirubin > the upper limit of normal\nnot due to Gilbert’s syndrome) or active hepatic viral infection due to the\nhigh risk of acute serious liver injury and acute liver failure.\n\n * Recent vaccination (within 4 weeks of treatment) due to immunogenicity and\npotential safety concerns.\n\n * Active or recent (within 4 weeks) infections due to safety concerns.\n\nIMPORTANT SAFETY INFORMATION\n\nBOXED WARNING: Acute Serious Liver Injury and Acute Liver Failure\n\nAcute serious liver injury, including life-threatening and fatal acute liver\nfailure, has occurred. Patients with preexisting liver impairment may be at\nhigher risk.\n\nPrior to infusion, assess liver function by clinical examination and\nlaboratory testing. Administer systemic corticosteroids before and after\nELEVIDYS infusion. Continue to monitor liver function weekly for the first 3\nmonths after infusion and continue until results are unremarkable.\n\nInstruct patients to maintain proximity to an appropriate healthcare facility,\nas determined by the healthcare provider, for at least 2 months following\nELEVIDYS infusion.\n\nObtain prompt consultation with a specialist (e.g., gastroenterologist or\nhepatologist) if acute serious liver injury or impending acute liver failure\nis suspected.\n\nCONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in\nexon 8 and/or exon 9, including a deletion of any portion or the entirety of\nthese exons, in the DMD gene.\n\nWARNINGS AND PRECAUTIONS:\n\nAcute Serious Liver Injury and Acute Liver Failure\n\nSee Boxed Warning.\n\n\n * Acute serious liver injury marked by elevations of liver enzymes (e.g., GGT,\nALT) and total bilirubin and acute liver failure has occurred with ELEVIDYS.\nOnset of the liver injury typically begins within 8 weeks of ELEVIDYS\nadministration. In non-ambulatory patients treated with ELEVIDYS, acute liver\nfailure with fatal outcome has occurred in the clinical and post-marketing\nsettings.\n\n * Life-threatening mesenteric vein thrombosis, complicated by bowel ischemia and\nnecrosis, and portal hypertension have been reported following acute liver\ninjury associated with ELEVIDYS in a non-ambulatory patient.\n\n * Patients with preexisting liver impairment, chronic hepatic condition, or\nacute liver disease (e.g., acute hepatic viral infection) may be at higher\nrisk of acute serious liver injury or acute liver failure. Postpone ELEVIDYS\nadministration in patients with acute liver disease until resolved or\ncontrolled.\n\n * Systemic corticosteroid treatment is recommended for patients before and after\nELEVIDYS infusion. Adjust corticosteroid regimen when indicated.\n\nSerious Infections\n\n\n * Increased susceptibility to serious infections may occur due to concomitant\nadministration of corticosteroid regimen and additional immunosuppressants,\nand ELEVIDYS. Serious respiratory infections, including with fatal outcomes,\nhave occurred in patients taking immunosuppressant corticosteroids required\nfor ELEVIDYS administration.\n\n * Monitor patients for signs and symptoms of infection before and after ELEVIDYS\nadministration and treat appropriately.\n\n * Administer immunizations according to best clinical practices and immunization\nguidelines prior to initiation of the corticosteroid regimen required before\nELEVIDYS infusion.\n\n * Avoid administration of ELEVIDYS to patients with active infections.\n\nMyocarditis\n\n\n * Acute, serious, life-threatening myocarditis and troponin-I elevations have\nbeen observed within 24 hours to more than 1 year following ELEVIDYS infusion.\n\n * If a patient experiences myocarditis, those with pre-existing left ventricle\nejection fraction (LVEF) impairment may be at higher risk of adverse outcomes.\n\n * Monitor troponin-I before ELEVIDYS infusion and weekly for the first month\nfollowing infusion and continue monitoring if clinically indicated, until\nresults return to near baseline levels or stabilize.\n\n * More frequent monitoring may be warranted in the presence of cardiac symptoms,\nsuch as chest pain or shortness of breath.\n\n * Advise patients to contact a physician immediately if they experience cardiac\nsymptoms.\n\nInfusion-related Reactions\n\n\n * Infusion-related reactions, including hypersensitivity reactions and\nanaphylaxis, have occurred during or up to several hours following ELEVIDYS\nadministration. Closely monitor patients during and for at least 3 hours after\nthe end of infusion. If symptoms of infusion-related reactions occur, slow or\nstop the infusion and give appropriate treatment. Once symptoms resolve, the\ninfusion may be restarted at a lower rate.\n\n * ELEVIDYS should be administered in a setting where treatment for\ninfusion-related reactions is immediately available.\n\n * Discontinue infusion for anaphylaxis.\n\nImmune-mediated Myositis\n\n\n * Immune-mediated myositis, including serious and life-threatening events, has\noccurred approximately 1 month following ELEVIDYS infusion. Signs and symptoms\ninclude severe muscle weakness, including dysphagia, dyspnea, dysphonia, and\nhypophonia.\n\n * Severe to life-threatening immune-mediated myositis has been reported in\npatients with deletions including portions of exons 1-17 and/or exons 59-71 of\nthe DMD gene.\n\n * Regardless of genetic mutation, advise patients to contact a physician\nimmediately if they experience any unexplained increased muscle pain,\ntenderness, or weakness, including dysphagia, dyspnea, dysphonia, or\nhypophonia, as these may be symptoms of myositis. Consider additional\nimmunomodulatory treatment based on patient’s clinical presentation and\nmedical history if these symptoms occur.\n\nPreexisting Immunity against AAVrh74\n\n\n * In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede\ntransgene expression at desired therapeutic levels. Following treatment with\nELEVIDYS, all patients developed anti-AAVrh74 antibodies.\n\n * Perform baseline testing for the presence of anti-AAVrh74 total binding\nantibodies prior to ELEVIDYS administration.\n\n * ELEVIDYS administration is not recommended in patients with elevated\nanti-AAVrh74 total binding antibody titers ≥1:400.\n\nADVERSE REACTIONS\n\n\n * The most common adverse reactions (incidence ≥5%) reported in clinical\nstudies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and\ntroponin-I increased.\n\nReport negative side effects of prescription drugs to the FDA. Visit\nwww.fda.gov/medwatch\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=www.fda.gov%2Fmedwatch&index=3&md5=1a4c6e29d825d3121d98375c8ecd7bf7)\nor call 1-800-FDA-1088. You may also report side effects to Sarepta\nTherapeutics at 1-888-SAREPTA (1-888-727-3782).\n\nPlease see the full Prescribing Information\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Felevidys.com%2FPI&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=Prescribing+Information&index=4&md5=a2312ade004cd5946c44f083063b6f9c)\nfor ELEVIDYS, including Boxed Warning and Medication Guide\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.elevidys.com%2Fmed-guide&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=Medication+Guide&index=5&md5=143306c16000933c4a1065b0ef7083d2)\n.\n\nAbout Sarepta Therapeutics\n\nSarepta is on an urgent mission: engineer precision genetic medicine for rare\ndiseases that devastate lives and cut futures short. We hold a leadership\nposition in Duchenne muscular dystrophy (Duchenne) and are building a robust\nportfolio of programs across muscle, central nervous system, and cardiac\ndiseases. For more information, please visit www.sarepta.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sarepta.com&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=www.sarepta.com&index=6&md5=0d1e7f4e43ee53068f457b34bba888a0)\nor follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsarepta-therapeutics&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=LinkedIn&index=7&md5=1bcdf426a751607b7b9f1f1d88d50d29)\n, X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FSarepta&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=X&index=8&md5=f70077901282b9171c609cd7672dbddd)\n, Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.instagram.com%2Fsareptatherapeutics%2F&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=Instagram&index=9&md5=cd7c7c007249b00b56cab397d5ca2272)\nand Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.facebook.com%2FSarepta-Therapeutics-208950446535427%2F&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=Facebook&index=10&md5=d58e8ab85429b0c97863726e54ed8a14)\n.\n\nInternet Posting of Information\n\nWe routinely post information that may be important to investors in the 'For\nInvestors' section of our website at www.sarepta.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sarepta.com%2F&esheet=54610583&newsitemid=20260925573264&lan=en-US&anchor=www.sarepta.com&index=11&md5=0f6992ff0ec4075243b99704bb2b3597)\n. We encourage investors and potential investors to consult our website\nregularly for important information about us.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260925573264/en/\n(https://www.businesswire.com/news/home/20260925573264/en/)\n\nInvestor Contacts:\n\nIan Estepan, 617-274-4052, iestepan@sarepta.com \n(mailto:iestepan@sarepta.com) \nRyan Wong, 617-800-4112, rwong@sarepta.com \n(mailto:rwong@sarepta.com) \nTam Thornton, 617-803-3825, tthornton@sarepta.com\n(mailto:tthornton@sarepta.com)\n\nMedia Contacts:\n\nTracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com \n(mailto:tsorrentino@sarepta.com) \nKara Hoeger, 617-710-3898, khoeger@sarepta.com (mailto:khoeger@sarepta.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-25T12:30:00.277811923Z","server_sent_at_ms":1790339400277},"received_at":"2026-09-25T12:30:00.482Z","source_url":"https://www.businesswire.com/news/home/20260925573264/en/"},"analysis":{"id":"141855","press_release_id":"153051","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Sarepta will present new Duchenne muscular dystrophy data at the 31st Annual Congress of the World Muscle Society, Sept. 29 - Oct. 3, in Hiroshima, Japan.\n\nPresentations include a late-breaking poster on ELEVIDYS efficacy and safety in older ambulatory patients aged 8-12 at treatment, plus EMBARK three-year outcomes and pooled Phase 1-3 safety analyses.\n\nData will be posted to Sarepta's investor relations site after presentation; the release is routine scientific communications with no new regulatory or financial disclosures.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference data slate for ELEVIDYS and exon-skipping franchise -- monitor actual poster data Sept. 30."},"keyFigures":{"drugName":"ELEVIDYS (delandistrogene moxeparvovec-rokl)","phaseOfTrial":"Phase 1 to Phase 3 (pooled safety); EMBARK, ENDEAVOR, ENVOL, ESSENCE studies","customDimensions":{"posterCount":7}},"quotedText":"a late-breaking poster presentation on delandistrogene moxeparvovec efficacy and safety in older, ambulatory Duchenne patients","namedEntities":{"people":[{"name":"C. McDonald","role":"study investigator"},{"name":"J. Mendell","role":"study investigator"},{"name":"C. Proud","role":"study investigator"},{"name":"N. Pukos","role":"study investigator"},{"name":"F. Muntoni","role":"study investigator"}],"products":["ELEVIDYS (delandistrogene moxeparvovec-rokl)","golodirsen","casimersen"],"companies":[{"name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Conference presentation announcement of existing clinical data (posters on ELEVIDYS, golodirsen/casimersen) with no new headline results, regulatory action, or financial impact."},"tickerRelevance":{"others":[],"primary":"SRPT"},"globalImportance":20,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap-biotech","eventGravity":"conference-presentation-announcement","issuerAuthored":true,"retailFavoriteBoost":"moderate-DMD-community-interest"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Sarepta will present new Duchenne muscular dystrophy data at the 31st Annual Congress of the World Muscle Society, Sept. 29 - Oct. 3, in Hiroshima, Japan.\n\nPresentations include a late-breaking poster on ELEVIDYS efficacy and safety in older ambulatory patients aged 8-12 at treatment, plus EMBARK three-year outcomes and pooled Phase 1-3 safety analyses.\n\nData will be posted to Sarepta's investor relations site after presentation; the release is routine scientific communications with no new regulatory or financial disclosures.","key_figures":{"drugName":"ELEVIDYS (delandistrogene moxeparvovec-rokl)","phaseOfTrial":"Phase 1 to Phase 3 (pooled safety); EMBARK, ENDEAVOR, ENVOL, ESSENCE studies","customDimensions":{"posterCount":7}},"named_entities":{"people":[{"name":"C. McDonald","role":"study investigator"},{"name":"J. Mendell","role":"study investigator"},{"name":"C. Proud","role":"study investigator"},{"name":"N. Pukos","role":"study investigator"},{"name":"F. Muntoni","role":"study investigator"}],"products":["ELEVIDYS (delandistrogene moxeparvovec-rokl)","golodirsen","casimersen"],"companies":[{"name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-25T12:30:06.265Z","global_importance":20,"audience_relevance":30,"importance_components":{"tickerTier":"mid-cap-biotech","eventGravity":"conference-presentation-announcement","issuerAuthored":true,"retailFavoriteBoost":"moderate-DMD-community-interest"}},"durationMs":5737,"modelName":"glm-5.3-flashx"}}